MicroRNA‑mediated regulation in lung adenocarcinoma: Signaling pathways and potential therapeutic implications (Review)
- Authors:
- Published online on: October 18, 2023 https://doi.org/10.3892/or.2023.8648
- Article Number: 211
-
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Abstract
Introduction
Lung cancer has one of the highest cancer incidence rates globally (1). It is the leading cause of cancer-related deaths, with a five-year survival rate of only 15% (2). Among the numerous pathological tissue types, adenocarcinoma is the most prevalent (3). The prognosis of lung adenocarcinoma (LUAD) is often poor due to tumor heterogeneity, delayed diagnosis and drug resistance (4). Despite the emergence of new therapies, including immunotherapy and targeted therapy, LUAD remains a global public health concern (5). Moreover, fluctuations in oncogene expression patterns and a limited understanding of LUAD pathogenesis have caused bottlenecks in the development of effective treatments for LUAD (6). Therefore, genomic medicine has increasingly gained prominence as an essential topic to address the gaps in tumor pathogenesis research.
~2% of the human genome encodes proteins (7). The remaining 98% of the non-coding portion has received considerable scientific attention over the past few decades (8). Previous studies have demonstrated that non-coding RNA (ncRNA) is involved in various cellular and physiological processes (9). They have been found to play a role in human health and pathological conditions such as LUAD (10). MicroRNAs (miRNAs) are endogenous ncRNAs that play crucial roles in the post-transcriptional regulation of genes. Accumulating evidence confirms that miRNAs are involved in the regulation of LUAD via specific pathways. The expression of these miRNAs indicates the emergence of an active signaling marker (11). The present review analyzed the role of miRNAs in LUAD development and highlighted the potential pathways involved.
General characteristics of miRNAs and mode of action
miRNAs are a class of non-coding single-stranded RNA molecules with lengths of ~22–24 nucleotides. They are widely present in animals, plants and viruses (12). Pri-miRNA is produced by RNA polymerase II via a clear miRNA-processing mechanism (13). Subsequently, pri-miRNA is transformed into pre-miRNA through the processing of RNase III, Drosha and DGCR8 (14). DGCR8 identifies double-stranded structures and recruits substrates (15). Drosha is responsible for cleaving pri-miRNAs. This process occurrs as the first shear in the nucleus. The newly generated pre-miRNA is transferred to the cytoplasm through RANGTP/exportin-5 (16).
The ribonuclease Dicer then combines with the TRBP protein to synthesize a mature double-stranded miRNA from pre-miRNA (17). In the process of assembling miRNA particles, the RNA helicase separates the two strands of duplex miRNA (18). The 5′ end of the single strand forms an active double strand with its partner, which enters a complex containing miRNA and ribonucleoprotein particles (19). The other strand breaks down (20). After a series of reactions, single-stranded miRNAs combine with Argonaute (2) in RNA-induced silencing complexes and then bind to the 3′ untranslated region of the target mRNA, leading to translation suppression or de-adenylation (Fig. 1) (21). In recent years, numerous studies have confirmed that miRNAs are associated with numerous diseases, such as diabetic kidney disease (22) and neurodegenerative disorders (23). In addition, miRNAs are known to participate in various malignant biological behaviors of tumors, such as proliferation and epithelial-mesenchymal transition (EMT) (24,25) (Table I).
Determination of miRNAs in LUAD
RNA microarrays and sequencing have been widely used to screen differentially expressed miRNAs in LUAD. The results were validated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) (102). Bioinformatics was employed to identify downstream target genes and enriched pathways (103). Petkova et al (104) used 12 pairs of tissues to screen 107 significantly dysregulated miRNAs through microarrays and performed RT-qPCR validation on the obtained results using 50 pairs of samples. A total of eight significantly differentially expressed miRNAs were successfully validated. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses revealed enrichment in the cell cycle, gene expression and EGFR pathways. The present study highlighted the potential of exploring differential miRNA expression profiles to understand their impact on tumor diagnosis and prognosis (104). Beyond human 365, it can also be detected in plasma. Jin et al (105) performed next-generation sequencing on samples from 16 patients with LUAD and 12 healthy individuals. Subsequently, a validation set including 10 LUAD patients and 30 healthy individuals was used to confirm significant differential expression of four miRNAs, including miR-181-5p. These miRNAs were further evaluated for diagnostic accuracy in an additional 60 patients initially diagnosed with non-small cell lung cancer, resulting in an area under curve (AUC) value of 0.936. These results revealed that these miRNAs may be promising biomarkers for diagnosing LUAD (105).
Role of miRNA in LUAD
Various studies have shown that miRNAs play an important role in regulating tumor biological behavior and influencing the tumor microenvironment (106,107). Numerous miRNAs have been recognized as tumor markers and therapeutic targets that play prominent roles in tumor prevention, diagnosis and treatment (108). Next, the roles of miRNAs in LUAD were investigated.
miRNAs as biomarkers in LUAD
Over the past 20 years, studies have confirmed that miRNAs can serve as biomarkers of malignant tumors, including LUAD (109,110). Tong et al (111) found that miRNA-365 is significantly downregulated in LUAD, and its expression is associated with tumor invasion and migration as well as patient survival. Meanwhile, miR-365 upregulates ETS1 expression and inhibits EMT by inactivating the AKT/mTOR pathway (111). Kim et al (112) also reported that high miRNA-130b expression is significantly associated with unfavorable clinicopathological parameters and poor survival outcomes in LUAD. Another study revealed a significant decrease in miR-339-5p expression in LUAD tissues and plasma, whereas miR-21 expression was significantly elevated. Receiver operating curve analysis demonstrated that they could be distinguished from normal control individuals through the AUC. This result confirmed the role of miRNAs in the early screening of LUAD (113). These miRNAs may serve as targeted tools for the diagnosis and evaluation of LUAD prognosis. Several studies have demonstrated that miRNAs are involved in the biological processes of LUAD in addition to acting as biomarkers. Subsequently, a series of specific miRNA functions were presented to demonstrate their significant roles in LUAD.
Role of miRNAs in the malignant biological behavior of LUAD: Cell proliferation and apoptosis
Cell proliferation and apoptosis are common in tumors. Together, they constitute the ‘minimum platform’ for the further development of tumors (114). To date, research on miRNAs in the field of tumor cell proliferation and apoptosis has been the most extensive. MiR-144-5p is considered a tumor suppressor gene in ovarian and lung cancers. It is involved in almost all stages of tumor development (115,116). Luo et al (28) found a negative regulatory relationship between miR-144-5p and CDCA3; miR-144-5p inhibited cell proliferation and promoted apoptosis through the interaction between CDCA3 and p53 signaling pathways. This result indicated that the downregulation of miR-144-5p had an antitumor effect by affecting the activation of p53.
Another study confirmed that miR-195-5p is expressed at low levels in LUAD and can negatively upregulate its target gene, TrxR2. MiR-195-5p inhibits cell proliferation by arresting the cell cycle phase (39). A previous study revealed that miR-3941 was significantly downregulated in LUAD tissues and cells, and miR-3941 bound to IGBP1, thereby inhibiting its transcription. Overexpression of miR-3941 not only inhibited the cell cycle but also induced the production of caspase-3 (44). Previous studies also demonstrated that other miRNAs, such as miR-383-5p, miR-335-3p, and miR-216b-3p, were all downregulated in LUAD, inhibited cell proliferation, and promoted apoptosis (43,45,54).
Correspondingly, various tumor promoters, such as miR-516a-3p, have been reported to promote cancer cell proliferation and inhibit apoptosis by regulating PTPRD expression. Researchers also found a significant relationship between the expression of miR-516a-3p and the clinical staging of LUAD (61). Thus, these molecules are potential targets for the diagnosis and treatment of LUAD.
Correlation of miRNA with LUAD invasion and metastasis
As a malignant tumor, LUAD can grow rapidly in situ and spread to distal organs via blood circulation and lymphatic tissue (117). Invasion and metastasis are important factors in the sustained progression of LUAD, and their mutual influence leads to lower survival rates (118). Strong evidence suggests that miRNAs participate in tumor invasion and metastasis by regulating the expression of their target genes. Mo et al (29) validated the differential expression of miR-145 in LUAD tissues and found that the upregulation of miR-145 inhibited the invasion and metastasis of SPC-A1 and A549 cell lines. They also confirmed that miR-145 mediated this process by influencing the translation of N-cadherin, a known cell adhesion molecule. At the clinical level, the findings revealed a strong correlation between low miR-145 expression and a high metastasis rate (29). Furthermore, a previous study demonstrated that miR-937-3p promotes the angiogenesis, invasion and metastasis of LUAD cells. MiR-937-3p has been reported to simultaneously regulate E-cadherin, vimentin, Slug and N-catenin, all of which are considered classic biomarkers of angiogenesis. Moreover, additional evidence was provided that the upstream oncogenic factor (MYC) of miR-937-3p binds to and upregulates its promoter region (37). Wu et al (48) demonstrated that miR-196b is upregulated in LUAD and is significantly correlated with an adverse prognosis. The knockdown of miR-196b delayed the invasion and metastasis of LUAD cells (48).
EMT is a cellular process in which cells lose their epithelial and interstitial properties. During tumor evolution, EMT is closely related to tumor occurrence, metastasis and treatment resistance (119). Long et al (26) showed that miR-214 is overexpressed in LUAD and promotes metastasis and EMT by regulating Sufu. During this process, epithelial and interstitial marker genes showed significant changes in opposite directions. Simultaneously, knockdown of miR-214 was shown to suppress EMT activity (26).
Other miRNAs, such as miR-485, miR-138-5p and miR-1827, regulate EMT in LUAD cells and affect LUAD progression. These miRNAs are associated with tumor invasion and metastasis and are related to an unfavorable prognosis and malignancy (50,55,60). However, the role of miRNAs in monitoring prognosis and delaying the progression of LUAD requires further exploration.
miRNA-regulated drug resistance and radiation sensitivity in LUAD
Drug resistance and reduced sensitivity to radiotherapy can lead to treatment failure and tumor recurrence (120,121). miRNAs are considered to induce the corresponding mechanisms in LUAD to improve drug resistance or radiation sensitivity. Cao et al (36) found that miR-192 was significantly upregulated in A549 cells and that LUAD mice carrying miR192 inhibitors were more sensitive to cisplatin and gemcitabine treatment. Moreover, in the process of improving chemotherapy resistance, Bcl-2 is upregulated as a key regulatory factor following miR-192 knockdown (36). Thus, miR-192 may be a potential target for LUAD chemotherapy. Another miRNA, miRNA-134, has been shown to be associated with multiple-drug resistance in LUAD. MiR-134 has been reported to be significantly downregulated in cisplatin-resistant LUAD cells. Further studies have shown that miR-134 overexpression enhances the sensitivity of LUAD cells to vincristine and 5-fluorouracil (51). Yuan et al (40) confirmed that the upregulation of miR-195-5p promotes the expression of Bax and reduces the expression of cyclin D1 and Bcl-2 in A549 and PC9 cells exposed to ionizing radiation. This result indicated that miR-195-5p enhanced the radiosensitivity of LUAD cells by promoting apoptosis (40). In summary, different miRNAs participate in LUAD progression by influencing the downstream target genes. They play an important role in the different phenotypes of LUAD.
miRNA-mediated targeting of specific signaling pathways in LUAD
miRNAs play an undeniable role in LUAD, yet, the specific molecular mechanism remains controversial. Generally, these molecules regulate tumor development by targeting downstream genes in multiple signaling pathways (122) (Table II).
AKT signaling pathway
Akt, also known as protein kinase B, is a key medium for GF-induced cell survival (164). Upregulation of Akt activity has been observed in numerous cancers. The interaction between tumor suppressors and tumor-promoting factors in the Akt pathway leads to proliferation, differentiation and inhibition of tumor cell apoptosis (165). The Akt pathway mediates by transporting signals from upstream regulatory proteins (such as PTEN and PI3K) to downstream effector proteins (MDM2 and FOXO). Subsequently, these effectors intersect with numerous other compensatory signaling pathways (166). Furthermore, miRNAs impact tumor progression by interfering with the expression of related genes in the Akt pathway (167). The roles of miRNAs in LUAD progression via the Akt pathway were summarized.
Downregulation of miR-382-3p has been shown to contribute to LUAD carcinogenesis. Fang et al (128) found that miR-382-3p inhibition promotes proliferation and inhibits apoptosis in LUAD cells by mediating SAE1, which is considered a key member of the SUMO activation complex. The aforementioned study further verified that upregulation of SAE1 increases SUMO1 and pAkt protein levels. In summary, low miR-382-3p expression promotes LUAD progression by promoting SUMO protein modification and Akt phosphorylation.
MiR-200 is considered to promote cancer cell growth via the PI3K/Akt pathway, with FOG2 as its downstream target. However, the FOG2 knockdown had almost no effect on Akt activation. Guo et al (140) confirmed that the activation of Akt by miR-200 was accompanied by the inactivation of p70S6K and significant upregulation of IRS-1, which is considered a substrate of p70S6K. More importantly, the knockdown of IRS-1 inhibited Akt phosphorylation, indicating that miR-200 activates Akt via IRS-1.
Similarly, miR-381 and miR-409-3p inhibited proliferation and reduced invasion and migration by regulating the Akt signaling pathway (147,149). Notably, He et al (125) found that miR-3613-5p acts as an intermediate hub, promoting LUAD progression. The upregulation of miR-3613-5p was mediated by RELA as a subunit of nuclear factor-kB (NF-kB) through JUN. Subsequently, miR-3613-5p stimulates the Akt/MAPK pathway via NR5A2. In addition, the phosphorylation of Akt1 and MAPK3/1 jointly activates RELA. From this, it could be observed that a RELA/JUN/miR-3613-5p/NR5A2/Akt/MAPK forward feedback loop had been established in the progress of LUAD. Therefore, the pathway mediated by a miRNA in LUAD is not unique and includes multiple overlapping pathways and upstream and downstream pathways forming feedback loops.
STAT3 signaling pathway
Signal transducer and activator of transcription (STAT) proteins are a family of cytoplasmic transcription factors that include STAT5a, STAT4, and STAT3 that regulate numerous signaling pathways. STAT3 is associated with diverse biological processes, including cell proliferation, apoptosis and differentiation (168). Lv et al (143) found that miR-320a not only regulates STAT3 but also affects its related signals, such as Bcl-2, Bax and Caspase8 to suppress the proliferation and metastasis of LUAD in vivo and in vitro. It is well known that certain cytokines, such as interleukin-6 (IL-6), bind to corresponding receptors on the cell membrane to activate the JAK2-STAT3 signaling pathway (169). MiR-204 and miR-425 were based on this mechanism to suppress the malignant biological behavior of LUAD (141,151). In addition, Xu et al (162) confirmed from another perspective that miR-30e-5p targets the upregulation of USP22 and mediates the Sirt1/JAK2/STAT3 pathway, which also inhibits LUAD.
Wnt signaling pathway
The Wnt pathway is a critical signaling cascade in cancer. Abnormal Wnt signaling is observed in numerous cancers, including LUAD. The Wnt signaling pathway mainly affects the stability, migration and immune escape of cancer stem cells (170). Additionally, signaling pathways, such as the Wnt and Notch pathways, typically form a network within cells to jointly regulate tumor progression (171). MiR-1275 has been reported to be significantly upregulated in LUAD. This trend increased the expression of β-catenin in the Wnt pathway and NICD in the Notch pathway. This miRNA also directly targets and inhibits negative regulatory factors, such as GSK3, RUNX3 and NUMB, in two signaling pathways. This enhances the stem cell phenotype of LUAD cells (123).
Coincidentally, miR-33b, miR-149,and miR-490-3p inhibit the malignant progression of LUAD through the Wnt/β-catenin signaling pathway. Their main mechanism of action is to reduce catenin expression to inhibit tumor cell proliferation, metastasis and EMT (132,137,153).
MTOR signaling pathway
The mammalian target of rapamycin (mTOR), a serine/threonine kinase, combines hormones, cytokines, nutrients and other factors to regulate biological behaviors including proliferation, differentiation and metabolism of cancer cells (172). It has two different complex forms in cells, mTORC1 and mTORC2, and its C-terminus is homologous to the catalytic domain of phosphatidylinositol kinase (PI3K). mTOR itself does not possess esterase kinase activity but rather has Ser/Thr protein kinase activity (173).
MiR-125 has been shown to inhibit LUAD. It also reduced the p-AKT/AKT ratio, the p-mTOR/mTOR ratio and the expression of RhoA by downregulating TNS1 (154). Additionally, miR-363-3p inhibited the proliferation and metastasis of LUAD cells through the mTOR/4EBP-1 and ERK signaling pathways (145). Evidently, the effect of miRNA on cancer often occurs in a multi-pathway and multi-target manner.
LUAD treatment with cisplatin can lead to multiple tolerances in malignant cells. This can cause the cancer cells to lose their sensitivity to drugs, leading to treatment failure. Cisplatin resistance is a major bottleneck in the treatment of LUAD (174). However, some studies have confirmed that miRNAs affect cisplatin resistance in LUAD through the mTOR signaling pathway. Liu et al (138) reported that the overexpression of miR-181 in A549/DDP cells (a LUAD drug-resistant cell line) promoted autophagy and upregulated the expression of LC3 and AGT5 proteins through the PTEN/PI3K/AKT/mTOR signaling pathway. Additionally, downregulation of miR-21 in A549/DDP cells slowed the loss of glucose and the production of pyruvic acid and lactic acid, which promoted the expression of apoptosis-related proteins. This process inhibits glucose metabolism and promotes cell death via the PI3K/AKT/mTOR/HIF-1a pathway (130).
NF-κB signaling pathway
The NF-kB is not a single gene but a family of transcription factors involved in multiple biological processes (175). This signaling pathway not only participates in inflammation and immune response but also plays an important role in the occurrence and development of tumors (176).
Lin (129) reported that miR-1-3p binds to the promoter region of E2F8, thereby inhibiting the malignant phenotype of LUAD cells. During this process, upregulated miR-1-3p significantly negatively regulated NF-κB and STAT3 protein phosphorylation expression (129). MiR-125a-5p had an effect similar to that of miR-1-3p, except that its downstream target was replaced with TMPRSS4. After enhancing miR-125a-5p expression, the expression of IκBκ and cytoplasmic NF-κB was significantly increased, accompanied by a marked decrease in the expression of nuclear NF-κB and p-IκB. Therefore, miR-125a-5p inhibited LUAD by inactivating the NF-κB signaling pathway (134). Similarly, overexpression of miR-148b and miR-383 both inhibited the phosphorylation of p65 and IkBa proteins, leading to the inactivation of the NF-κB signaling pathway. This process suppresses LUAD progression and improves sensitivity to chemotherapy (148,156).
MAPK signaling pathway
The mitogen-activated protein kinase (MAPK) signaling pathway plays an important role in proliferation, differentiation and inflammation-related signaling pathways. It contains four branches, of which the main substrates are extracellular signal-related kinase (ERK) and Jun amino terminal kinase (JNK) (177). Among these, the MAPK/ERK signaling pathway has been associated with tumor-related malignant phenotypes such as cell proliferation and apoptosis (178).
MiR-6742-5p, miR-363-3p, miR-451 and miR-1258 are expressed at low levels in LUAD and inhibit cell proliferation. Mechanistically, they reduced the phosphorylation of the ERK1/2 protein through the ERK pathway, which is considered a classic branch of the MAPK signaling pathway (127,145,152,157). By contrast, miR-1307-5p and miR-25 participated in the regulation of LUAD as oncogenes through the ERK signaling pathway (127,159).
Other signaling pathways involved in LUAD
Numerous signaling pathways are involved in LUAD tumor regulation, with numerous miRNAs associated with these pathways. Ma et al (126) found that miR-6077 targeted GLUT1 (glucose transporter 1) and inhibited glucose absorption and lactate production after its upregulation. By mediating the glucose transport pathway, miR-6077 increased the sensitivity of LUAD cells to alotinib (126). Other miRNAs, such as miR-106a-5p, were upregulated in LUAD, and it has been shown to suppress the phosphorylation of AMPK and TSC2 proteins, while upregulating the phosphorylation of mTOR. This change promotes the proliferation and autophagy of tumor cells (133). Ghoshal-Gupta et al (135) showed that miR-125a-5p regulates apoptosis in LUAD cells by upregulating the p53 protein and altering the expression of other related apoptotic proteins, such as Bcl-2 and BAX. There are several additional examples. MiR-140-3p enhanced the sensitivity of LUAD cells to antitumor drugs by suppressing the Notch signaling pathway, and miR-182-5p plays a similar role through the Hedgehog pathway (136,139). Additionally, TGF β, Hippo, and YAP signaling pathways participated in the regulation of LUAD (142,158,160).
Interactions of lncRNA and circRNA with miRNA in LUAD
Recently, competing endogenous RNAs (ceRNAs) have garnered significant research interest as they represent a novel regulatory mechanism between RNAs, rather than representing a distinct type RNA (179). This theory reveals the presence of miRNA response elements (MREs) not only on mRNA but also on lncRNAs and circRNAs (180). Therefore, mRNA, lncRNAs and circRNAs compete with miRNAs to form complex regulatory networks that affect gene expression. Some lncRNAs and circRNAs interact with miRNAs and subsequently affect LUAD progression (Tables III and IV).
Yang et al (181) found that linc00483 is highly expressed in LUAD and positively correlated with poor prognosis. Moreover, it acted as a sponge for miR-204-3p in the cytoplasm and regulated ETS1. Another study revealed that HMMR-AS1 plays an important role as a ceRNA in the proliferation and metastasis of LUAD, which regulates the expression of SIRT6 through sponging miR-138 (183). Chen et al (184) demonstrated that HOXA11-AS suppresses the expression of miR-148b-3p by binding to its MREs. Subsequently, PKM2 expression is indirectly upregulated and plays a role in glycolysis in cancer cells (184). Numerous miRNAs, such as Linc00520 and Linc01833, are highly expressed in LUAD. They mainly promote cancer cells via the lncRNA/miRNA/mRNA axis (186–193,195). Indeed, lncRNAs exhibit inhibitory effects on cancer phenotypes in LUAD. Linc01089 is significantly underexpressed in LUAD and competitively binds to miR-301b-3p as a ceRNA. Moreover, miR-301b-3p interacted with STARD13, contributing to the proliferation and metastasis of LUAD (183). Recently, Liu et al (193) found that SGMS1-AS1 regulates MYLI9 through the competitive isolation of miR-106a-5p. A rescue experiment revealed that MYLI9 overexpression or miR-106a-5p inhibition offset the regulatory effect of SGMS1-AS1 silencing in LUAD cells (194).
Furthermore, multiple studies have confirmed that circRNAs regulate gene expression by suppressing miRNA activity (206). Circle_ 0006427 was significantly localized in the cytoplasm and was positively regulated by DKK1 through competitive sponging of miR-6783-3p in LUAD cells (195). Huang et al (199) reported that the overexpression of circ_000881 slowed the malignant phenotypes of LUAD cells. Furthermore, circRNA_000881 acts as a sponge for miR-665 and indirectly regulates the downstream target gene PRICKLE2 (199). Similarly, circ_0129047 and circ-MTO1 play similar roles as tumor suppressors in LUAD (201,202). Numerous circRNAs act as cancer promoters in LUAD. For example, circ-CAMK2A was not only significantly upregulated in LUAD but was also positively correlated with an unfavorable prognosis. It upregulates the expression of fibronectin 1 by competitively binding to miR-615-5p, thereby enhancing the expression of MMP9 and MMP2 and promoting LUAD progression (196). In summary, the circRNA-miRNA-mRNA axis plays a crucial role in LUAD (197,198,200,203–205).
Limitations and outlook
However, these experiments also have certain limitations. Firstly, in the article, the approach to revealing the mechanism is relatively singular. It is nothing more than verification at the tissue, cell and animal levels, and further verification through functional gene experiments and phenotype rescue experiments is required. Secondly, during experimental verification, the number of cell line types and tissue samples is relatively small. Thirdly, the current research on miRNAs remians in the basic experimental stage, and how to transition to clinical practice is an urgent issue that needs to be solved.
At present, although numerous miRNAs have been proven to have promoting or inhibiting effects on LUAD, the manipulation of miRNAs has not been translated into practical clinical treatment strategies. The reasons for this are multifaceted. Firstly, numerous miRNAs regulate tumor progression through different target genes and signaling pathways. Therefore, interfering with a single miRNA cannot fundamentally treat LUAD. Correspondingly, a method or drug that can alter the regulatory network targeting miRNAs should be developped. Secondly, the reagents required for overexpression or low expression of miRNAs in basic experiments are cytotoxic. In actual clinical treatment, this is clearly unacceptable. Thirdly, even if drugs that can interfere with miRNAs while being non-toxic are obtained, how to efficiently and safely enter the human organism remains a challenging issue.
Conclusions
Emerging evidence suggests that miRNAs are involved in the regulation of LUAD by degrading or silencing downstream target genes at the post-transcriptional level. miRNAs have been shown to regulate multiple malignant biological phenotypes of LUAD through multiple signaling pathways. The present review systematically summarized the roles of abnormally expressed miRNAs in LUAD and their related signaling pathways.
Research findings suggest that miRNAs hold promise as potential biomarkers of LUAD, and the signaling pathways that they influence could offer innovative targets for LUAD treatment. The interactions between ceRNAs and miRNAs present a novel mechanism for LUAD development. The lncRNA or circRNA/miRNA/mRNA axis has emerged as a major focus in cancer research. Continued investigation is likely to unveil additional miRNA-mediated signaling pathways and therapeutic targets for LUAD, enhancing diagnosis and treatment approaches for this disease.
However, basic research is not equivalent to clinical application. There are still numerous urgent problems to be solved in the treatment of LUAD using miRNAs. For example, there is a lack of effective means for overall intervention in miRNAs-regulatory networks. Meanwhile, drugs that interfere with miRNAs need to be proven to be effective and safe. These practical problems not only pose challenges, but also point in the direction of progress.
Acknowledgements
Not applicable.
Funding
The present study was supported by the 345 Talent Project of the Shengjing Hospital.
Availability of data and materials
Not applicable.
Authors' contributions
JL and FZ wrote the manuscript. YW and JW reviewed the article. All authors read and approved the final version of the manuscript. Data authentication is not applicable.
Ethics approval and consent to participate
Not applicable.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
References
|
Seguin L, Durandy M and Feral CC: Lung adenocarcinoma tumor origin: A guide for personalized medicine. Cancers (Basel). 14:17592022. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Z, Fillmore CM, Hammerman PS, Kim CF and Wong KK: Non-small-cell lung cancers: A heterogeneous set of diseases. Nat Rev Cancer. 14:535–546. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Davidson MR, Gazdar AF and Clarke BE: The pivotal role of pathology in the management of lung cancer. J Thorac Dis. 5 (Suppl 5):S463–S478. 2013.PubMed/NCBI | |
|
Zito Marino F, Bianco R, Accardo M, Ronchi A, Cozzolino I, Morgillo F, Rossi G and Franco R: Molecular heterogeneity in lung cancer: From mechanisms of origin to clinical implications. Int J Med Sci. 16:981–989. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Langer CJ, Besse B, Gualberto A, Brambilla E and Soria JC: The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol. 28:5311–5320. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Iqbal MA, Arora S, Prakasam G, Calin GA and Syed MA: MicroRNA in lung cancer: Role, mechanisms, pathways and therapeutic relevance. Mol Aspects Med. 70:3–20. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ishola AA, La'ah AS, Le HD, Nguyen VQ, Yang YP, Chou SJ, Tai HY, Chien CS and Wang ML: Non-coding RNA and lung cancer progression. J Chin Med. 83:8–14. 2020. | |
|
Esteller M: Non-coding RNAs in human disease. Nat Rev Genet. 12:861–874. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW, Rubagotti M, Goldstein AM, Linnoila I, Marincola FM, et al: MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res. 16:430–441. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Xie K, Zhou H, Wu Y, Li C, Liu Y, Liu Z, Xu Q, Liu S, Xiao D and Tao Y: Role of non-coding RNAs and RNA modifiers in cancer therapy resistance. Mol Cancer. 19:472020. View Article : Google Scholar : PubMed/NCBI | |
|
Hanna J, Hossain GS and Kocerha J: The potential for microRNA therapeutics and clinical research. Front Genet. 10:4782019. View Article : Google Scholar : PubMed/NCBI | |
|
Li G, Fang J, Wang Y, Wang H and Sun CC: MiRNA-based therapeutic strategy in lung cancer. Curr Pharm Des. 23:6011–6018. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Agrawal N, Dasaradhi PVN, Mohmmed A, Malhotra P, Bhatnagar RK and Mukherjee SK: RNA interference: Biology, mechanism, and applications. Microbiol Mol Biol Rev. 67:657–685. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Michlewski G and Cáceres JF: Post-transcriptional control of miRNA biogenesis. RNA. 25:1–16. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Guo WT and Wang Y: Dgcr8 knockout approaches to understand microRNA functions in vitro and in vivo. Cell Mol Life Sci. 76:1697–1711. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Lu TX and Rothenberg ME: MicroRNA. J Allergy Clin Immunol. 141:1202–1217. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Heyam A, Lagos D and Plevin M: Dissecting the roles of TRBP and PACT in double-stranded RNA recognition and processing of noncoding RNAs. Wiley Interdiscip Rev RNA. 6:271–289. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Linder P and Jankowsky E: From unwinding to clamping-the DEAD box RNA helicase family. Nat Rev Mol Cell Biol. 12:505–616. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Williams AE: Functional aspects of animal microRNAs. Cell Mol Life Sci. 65:545–562. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Du T and Zamore PD: microPrimer: The biogenesis and function of microRNA. Development. 132:4645–4652. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Treiber T, Treiber N and Meister G: Regulation of microRNA biogenesis and function. Thromb Haemost. 107:605–610. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ren H and Wang Q: Non-coding RNA and diabetic kidney disease. DNA Cell Biol. 40:553–567. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Gizak A, Duda P, Pielka E, McCubrey JA and Rakus D: GSK3 and miRNA in neural tissue: From brain development to neurodegenerative diseases. Biochim Biophys Acta Mol Cell Res. 1867:1186962020. View Article : Google Scholar : PubMed/NCBI | |
|
Hill M and Tran N: miRNA interplay: Mechanisms and consequences in cancer. Dis Model Mech. 14:dmm0476622021. View Article : Google Scholar : PubMed/NCBI | |
|
Lee YS and Dutta A: MicroRNAs in cancer. Annu Rev Pathol. 4:199–227. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Long H, Wang Z, Chen J, Xiang T, Li Q, Diao X and Zhu B: microRNA-214 promotes epithelial-mesenchymal transition and metastasis in lung adenocarcinoma by targeting the suppressor-of-fused protein (Sufu). Oncotarget. 6:38705–38718. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Han L, Huang Z, Liu Y, Ye L, Li D, Yao Z, Wang C, Zhang Y, Yang H, Tan Z, et al: MicroRNA-106a regulates autophagy-related cell death and EMT by targeting TP53INP1 in lung cancer with bone metastasis. Cell Death Dis. 12:10372021. View Article : Google Scholar : PubMed/NCBI | |
|
Luo J, Xia L, Zhang L, Zhao K and Li C: MiRNA-144-5p down-modulates CDCA3 to regulate proliferation and apoptosis of lung adenocarcinoma cells. Mutat Res. 825:1117982022. View Article : Google Scholar : PubMed/NCBI | |
|
Mo D, Yang D, Xiao X, Sun R, Huang L and Xu J: MiRNA-145 suppresses lung adenocarcinoma cell invasion and migration by targeting N-cadherin. Biotechnol Lett. 39:701–710. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yin R, Zhang S, Wu Y, Fan X, Jiang F, Zhang Z, Feng D, Guo X and Xu L: microRNA-145 suppresses lung adenocarcinoma-initiating cell proliferation by targeting OCT4. Oncol Rep. 25:1747–1754. 2011.PubMed/NCBI | |
|
Zhang JX, Yang W, Wu JZ, Zhou C, Liu S, Shi HB and Zhou WZ: MicroRNA-32-5p inhibits epithelial-mesenchymal transition and metastasis in lung adenocarcinoma by targeting SMAD family 3. J Cancer. 12:2258–2267. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Liu J, Si L and Tian H: MicroRNA-148a inhibits cell proliferation and cell cycle progression in lung adenocarcinoma via directly targeting transcription factor E2F3. Exp Ther Med. 16:5400–5409. 2018.PubMed/NCBI | |
|
Lu Y, Zheng W, Rao X, Du Y and Xue J: MicroRNA-9-5p facilitates lung adenocarcinoma cell malignant progression via targeting STARD13. Biochem Genet. 60:1865–1880. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu K, Lin J, Chen S and Xu Q: miR-9-5p promotes lung adenocarcinoma cell proliferation, migration and invasion by targeting ID4. Technol Cancer Res Treat. 20:153303382110485922021. View Article : Google Scholar : PubMed/NCBI | |
|
Han HS, Son SM, Yun J, Jo YN and Lee OJ: MicroRNA-29a suppresses the growth, migration, and invasion of lung adenocarcinoma cells by targeting carcinoembryonic antigen-related cell adhesion molecule 6. FEBS Lett. 588:3744–3750. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cao J, He Y, Liu HQ, Wang SB, Zhao BC and Cheng YS: MicroRNA 192 regulates chemo-resistance of lung adenocarcinoma for gemcitabine and cisplatin combined therapy by targeting Bcl-2. Int J Clin Exp Med. 8:12397–12403. 2015.PubMed/NCBI | |
|
Ma Z, Chen G, Chen Y, Guo Z, Chai H, Tang Y, Zheng L, Wei K, Pan C, Ma Z, et al: MiR-937-3p promotes metastasis and angiogenesis and is activated by MYC in lung adenocarcinoma. Cancer Cell Int. 22:312022. View Article : Google Scholar : PubMed/NCBI | |
|
Duan L, Wang J, Zhang D, Yuan Y, Tang L, Zhou Y and Jiang X: Immune-related miRNA-195-5p inhibits the progression of lung adenocarcinoma by targeting polypyrimidine tract-binding protein 1. Front Oncol. 12:8625642022. View Article : Google Scholar : PubMed/NCBI | |
|
Bu L, Tian Y, Wen H, Jia W and Yang S: miR-195-5p exerts tumor-suppressive functions in human lung cancer cells through targeting TrxR2. Acta Biochim Biophys Sin (Shanghai). 53:189–200. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan C, Bai R, Gao Y, Jiang X, Li S, Sun W, Li Y, Huang Z, Gong Y and Xie C: Effects of MicroRNA-195-5p on biological behaviors and radiosensitivity of lung adenocarcinoma cells via targeting HOXA10. Oxid Med Cell Longev. 2021:45222102021. View Article : Google Scholar : PubMed/NCBI | |
|
Cao X, Xue F, Chen H, Shen L, Yuan X, Yu Y, Zong Y, Zhong L and Huang F: MiR-202-3p inhibits the proliferation and metastasis of lung adenocarcinoma cells by targeting RRM2. Ann Transl Med. 10:13742022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhuang L, Shou T, Li K, Gao CL, Duan LC, Fang LZ, Zhang QY, Chen ZN, Zhang C, Yang ST and Li GF: MicroRNA-30e-5p promotes cell growth by targeting PTPN13 and indicates poor survival and recurrence in lung adenocarcinoma. J Cell Mol Med. 21:2852–2862. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao S, Gao X, Zang S, Li Y, Feng X and Yuan X: MicroRNA-383-5p acts as a prognostic marker and inhibitor of cell proliferation in lung adenocarcinoma by cancerous inhibitor of protein phosphatase 2A. Oncol Lett. 14:3573–3579. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Sato T, Shiba-Ishii A, Kim Y, Dai T, Husni RE, Hong J, Kano J, Sakashita S, Iijima T and Noguchi M: miR-3941: A novel microRNA that controls IGBP1 expression and is associated with malignant progression of lung adenocarcinoma. Cancer Sci. 108:536–542. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Pu X, Jiang H, Li W, Xu L, Wang L and Shu Y: Upregulation of the coatomer protein complex subunit beta 2 (COPB2) gene targets microRNA-335-3p in NCI-H1975 lung adenocarcinoma cells to promote cell proliferation and migration. Med Sci Monit. 26:e9183822020. View Article : Google Scholar : PubMed/NCBI | |
|
Hu WB, Wang L, Huang XR and Li F: MicroRNA-204 targets SOX4 to inhibit metastasis of lung adenocarcinoma. Eur Rev Med Pharmacol Sci. 23:1553–1562. 2019.PubMed/NCBI | |
|
Zhou Y, Zhao M, Du Y, Liu Y, Zhao G, Ye L, Li Q, Li H, Wang X, Liu X, et al: MicroRNA-195 suppresses the progression of lung adenocarcinoma by directly targeting apelin. Thorac Cancer. 10:1419–1430. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wu X, Wu G, Zhang H, Peng X, Huang B, Huang M, Ding J, Mao C and Peng C: MiR-196b promotes the invasion and migration of lung adenocarcinoma cells by targeting AQP4. Technol Cancer Res Treat. 20:15330338209858682021. View Article : Google Scholar : PubMed/NCBI | |
|
Pan L, Tang Z, Pan L and Tang R: MicroRNA-3666 inhibits lung cancer cell proliferation, migration, and invasiveness by targeting BPTF. Biochem Cell Biol. 97:415–422. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Mou X and Liu S: MiR-485 inhibits metastasis and EMT of lung adenocarcinoma by targeting Flot2. Biochem Biophys Res Commun. 477:521–526. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Chen Y, Jin M, Wang J, Li S, Chen Z and Yu W: MicroRNA-134 reverses multidrug resistance in human lung adenocarcinoma cells by targeting FOXM1. Oncol Lett. 13:1451–1455. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Gao Y, Xue Q, Wang D, Du M, Zhang Y and Gao S: miR-873 induces lung adenocarcinoma cell proliferation and migration by targeting SRCIN1. Am J Transl Res. 7:2519–2526. 2015.PubMed/NCBI | |
|
Liu L, Bi N, Wu L, Ding X, Men Y, Zhou W, Li L, Zhang W, Shi S, Song Y and Wang L: MicroRNA-29c functions as a tumor suppressor by targeting VEGFA in lung adenocarcinoma. Mol Cancer. 16:502017. View Article : Google Scholar : PubMed/NCBI | |
|
Chai Y, Xue H, Wu Y, Du X, Zhang Z, Zhang Y, Zhang L, Zhang S, Zhang Z and Xue Z: MicroRNA-216b-3p inhibits lung adenocarcinoma cell growth via regulating PDZ binding kinase/T-LAK-cell-originated protein kinase. Exp Ther Med. 15:4822–4828. 2018.PubMed/NCBI | |
|
Zhu D, Gu L, Li Z, Jin W, Lu Q and Ren T: MiR-138-5p suppresses lung adenocarcinoma cell epithelial-mesenchymal transition, proliferation and metastasis by targeting ZEB2. Pathol Res Pract. 215:861–872. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Wang F and Xu P: miR-590 accelerates lung adenocarcinoma migration and invasion through directly suppressing functional target OLFM4. Biomed Pharmacother. 86:466–474. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang M, Wang Y, Zang W, Wang H, Chu H, Li P, Li M, Zhang G and Zhao G: Downregulation of microRNA-182 inhibits cell growth and invasion by targeting programmed cell death 4 in human lung adenocarcinoma cells. Tumour Biol. 35:39–46. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Greenawalt EJ, Edmonds MD, Jain N, Adams CM, Mitra R and Eischen CM: Targeting of SGK1 by miR-576-3p inhibits lung adenocarcinoma migration and invasion. Mol Cancer Res. 17:289–298. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Fu Q, Li H, Zhu L, Chen W, Ruan T, Xu W and Yu X: MicroRNA-520c-3p functions as a novel tumor suppressor in lung adenocarcinoma. FEBS J. 286:2737–2752. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Fan G, Xu P and Tu P: MiR-1827 functions as a tumor suppressor in lung adenocarcinoma by targeting MYC and FAM83F. J Cell Biochem. 121:1675–1689. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wu A, Yang X, Zhang B, Wang S and Li G: miR-516a-3p promotes proliferation, migration, and invasion and inhibits apoptosis in lung adenocarcinoma by targeting PTPRD. Int J Clin Exp Pathol. 12:4222–4231. 2019.PubMed/NCBI | |
|
Qin E, Gu S, Guo Y, Wang L and Pu G: MiRNA-30a-5p/VCAN arrests tumor metastasis via modulating the adhesion of lung adenocarcinoma cells. Appl Biochem Biotechnol. Apr 10–2023.(Epub ahead of print). View Article : Google Scholar | |
|
Tao K, Liu J, Liang J, Xu X, Xu L and Mao W: Vascular endothelial cell-derived exosomal miR-30a-5p inhibits lung adenocarcinoma malignant progression by targeting CCNE2. Carcinogenesis. 42:1056–1067. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang G, Wu YJ and Yan F: MicroRNA-130-5p promotes invasion as well as migration of lung adenocarcinoma cells by targeting the EZH2 signaling pathway. Eur Rev Med Pharmacol Sci. 23:9480–9488. 2019.PubMed/NCBI | |
|
Dai B, Kong DL, Tian J, Liu TW, Zhou H and Wang ZF: microRNA-1205 promotes cell growth by targeting APC2 in lung adenocarcinoma. Eur Rev Med Pharmacol Sci. 23:1125–1133. 2019.PubMed/NCBI | |
|
Bai J, Hu Y, Chen X, Chen L, Zhang L, Yin C and Li H: miR-144-3p inhibits the invasion and metastasis of lung adenocarcinoma cells by targeting IRS1. Zhongguo Fei Ai Za Zhi. 24:323–330. 2021.(In Chinese). PubMed/NCBI | |
|
Liu K, Zhang W, Tan J, Ma J and Zhao J: MiR-200b-3p functions as an oncogene by targeting ABCA1 in lung adenocarcinoma. Technol Cancer Res Treat. 18:15330338198925902019. View Article : Google Scholar : PubMed/NCBI | |
|
Guo ZZ, Ma ZJ, He YZ, Jiang W, Xia Y, Pan CF, Wei K, Shi YJ, Chen L and Chen YJ: miR-550a-5p functions as a tumor promoter by targeting LIMD1 in lung adenocarcinoma. Front Oncol. 10:5707332020. View Article : Google Scholar : PubMed/NCBI | |
|
Sun Y, Zhao J, Yin X, Yuan X, Guo J and Bi J: miR-297 acts as an oncogene by targeting GPC5 in lung adenocarcinoma. Cell Prolif. 49:636–643. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y and Yang C: miR-197-3p-induced downregulation of lysine 63 deubiquitinase promotes cell proliferation and inhibits cell apoptosis in lung adenocarcinoma cell lines. Mol Med Rep. 17:3921–3927. 2018.PubMed/NCBI | |
|
Fang H, Liu Y, He Y, Jiang Y, Wei Y, Liu H, Gong Y and An G: Extracellular vesicle-delivered miR-505-5p, as a diagnostic biomarker of early lung adenocarcinoma, inhibits cell apoptosis by targeting TP53AIP1. Int J Oncol. 54:1821–1832. 2019.PubMed/NCBI | |
|
Qian T, Shi S, Xie L and Zhu Y: miR-938 promotes cell proliferation by regulating RBM5 in lung adenocarcinoma cells. Cell Biol Int. 44:295–305. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Cao J, Geng J, Chu X, Wang R, Huang G and Chen L: miRNA-885-3p inhibits docetaxel chemoresistance in lung adenocarcinoma by downregulating Aurora A. Oncol Rep. 41:1218–1230. 2019.PubMed/NCBI | |
|
Bao B, Yu X and Zheng W: MiR-139-5p targeting CCNB1 modulates proliferation, migration, invasion and cell cycle in lung adenocarcinoma. Mol Biotechnol. 64:852–860. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, He X, Wu X, Liu X, Huang Y and Gong Y: miR-139-5p inhibits lung adenocarcinoma cell proliferation, migration, and invasion by targeting MAD2L1. Comput Math Methods Med. 2020:29535982020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Zhou L, Chen B, Li X, Zou Q, Xu W, Fang L, Wu A, Li Z and Chen Y: microRNA-660 enhances cisplatin sensitivity via decreasing SATB2 expression in lung adenocarcinoma. Genes. 14:9112023. View Article : Google Scholar : PubMed/NCBI | |
|
Feng YY, Liu CH, Xue Y, Chen YY, Wang YL and Wu XZ: MicroRNA-147b promotes lung adenocarcinoma cell aggressiveness through negatively regulating microfibril-associated glycoprotein 4 (MFAP4) and affects prognosis of lung adenocarcinoma patients. Gene. 730:1443162020. View Article : Google Scholar : PubMed/NCBI | |
|
Wan S, Liu Z, Chen Y, Mai Z, Jiang M, Di Q and Sun B: MicroRNA-140-3p represses the proliferation, migration, invasion and angiogenesis of lung adenocarcinoma cells via targeting TYMS (thymidylate synthetase). Bioengineered. 12:11959–11977. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Kanmangne D, Li R, Qian Z, Xia X, Wang X and Wang T: miR-30a-3p suppresses the proliferation and migration of lung adenocarcinoma cells by downregulating CNPY2. Oncol Rep. 43:646–654. 2020.PubMed/NCBI | |
|
Chen L, Chen X, Liu L, Zhao Y, Zuo W, Yin C and Li H: miR-30b-3p inhibits the proliferation and invasion of lung adenocarcinoma by targeting COX6B1. Zhongguo Fei Ai Za Zhi. 25:567–574. 2022.(In Chinese). PubMed/NCBI | |
|
Tu Y and Mei F: miR-3648 promotes lung adenocarcinoma-genesis by inhibiting SOCS2 (suppressor of cytokine signaling 2). Bioengineered. 13:3044–3056. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Z, Cui Y, Wang S, Wu C, Mei F, Han E, Hu Z and Zhou B: MiR-96-5p is an oncogene in lung adenocarcinoma and facilitates tumor progression through ARHGAP6 downregulation. J Appl Genet. 62:631–638. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou F, Qian C, Chen T and Zang X: MiR-96-5p facilitates lung adenocarcinoma cell phenotypes by inhibiting FHL1. Comput Math Methods Med. 2022:78912222022. View Article : Google Scholar : PubMed/NCBI | |
|
Chen G, Wang Q and Wang K: MicroRNA-218-5p affects lung adenocarcinoma progression through targeting endoplasmic reticulum oxidoreductase 1 alpha. Bioengineered. 13:10061–10070. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Miao H, Zeng Q, Xu S and Chen Z: miR-1-3p/CELSR3 participates in regulating malignant phenotypes of lung adenocarcinoma cells. Curr Gene Ther. 21:304–312. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Li T, Wang X, Jing L and Li Y: MiR-1-3p inhibits lung adenocarcinoma cell tumorigenesis via targeting protein regulator of cytokinesis 1. Front Oncol. 9:1202019. View Article : Google Scholar : PubMed/NCBI | |
|
An JC, Shi HB, Hao WB, Zhu K and Ma B: miR-944 inhibits lung adenocarcinoma tumorigenesis by targeting STAT1 interaction. Oncol Lett. 17:3790–3798. 2019.PubMed/NCBI | |
|
Feng H, Zhang Z, Qing X, French SW and Liu D: miR-186-5p promotes cell growth, migration and invasion of lung adenocarcinoma by targeting PTEN. Exp Mol Pathol. 108:105–113. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Q and Xu Z: miR-196b-5p promotes proliferation, migration and invasion of lung adenocarcinoma cells via targeting RSPO2. Cancer Manag Res. 12:13393–13402. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lin R, Li GS, Gan XY, Peng JX, Feng Y, Wang LT, Zhang CY, Huang KY, Huang SH, Yang L, et al: The clinical significance and mechanism of microRNA-22-3p targeting TP53 in lung adenocarcinoma. Technol Health Care. 31:1691–1707. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Goto A, Tanaka M, Yoshida M, Umakoshi M, Nanjo H, Shiraishi K, Saito M, Kohno T, Kuriyama S, Konno H, et al: The low expression of miR-451 predicts a worse prognosis in non-small cell lung cancer cases. PLoS One. 12:e01812702017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang G, Zhou Y, Chen W, Yang Y, Ye J, Ou H and Wu H: miR-21-5p promotes lung adenocarcinoma cell proliferation, migration and invasion via targeting WWC2. Cancer Biomark. 28:549–559. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wei D: MiR-486-5p specifically suppresses SAPCD2 expression, which attenuates the aggressive phenotypes of lung adenocarcinoma cells. Histol Histopathol. 37:909–917. 2022.PubMed/NCBI | |
|
Yang W, Bai J, Liu D, Wang S, Zhao N, Che R and Zhang H: MiR-93-5p up-regulation is involved in non-small cell lung cancer cells proliferation and migration and poor prognosis. Gene. 647:13–20. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Shao L, He Q, Wang J, He F, Lin S, Wu L, Gao Y, Ma W, Dong J, Yang X and Li F: MicroRNA-326 attenuates immune escape and prevents metastasis in lung adenocarcinoma by targeting PD-L1 and B7-H3. Cell Death Discov. 7:1452021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao J, Yu H, Han T and Zhu X: Prognosis value of microRNA-3677-3p in lung adenocarcinoma and its regulatory effect on tumor progression. Cancer Manag Res. 13:9261–9270. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Ling DJ, Chen ZS, Zhang YD, Liao QD, Feng JX, Zhang XY and Shi TS: MicroRNA-145 inhibits lung cancer cell metastasis. Mol Med Rep. 11:3108–3114. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang HB, Shen B, Ma ZC, Xu YY, Lou YL and Chen M: MiR-593-5p inhibited proliferation and migration of lung adenocarcinoma by targeting ICAM-1. Eur Rev Med Pharmacol Sci. 24:4298–4305. 2020.PubMed/NCBI | |
|
Huang JY, Cui SY, Chen YT, Song HZ, Huang GC, Feng B, Sun M, De W, Wang R and Chen LB: MicroRNA-650 was a prognostic factor in human lung adenocarcinoma and confers the docetaxel chemoresistance of lung adenocarcinoma cells via regulating Bcl-2/Bax expression. PLoS One. 8:e726152013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhuo E, Cai C, Liu W, Li K and Zhao W: Downregulated microRNA-140-5p expression regulates apoptosis, migration and invasion of lung cancer cells by targeting zinc finger protein 800. Oncol Lett. 20:3902020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Xiao H, Wu D, Zhang D and Zhang Z: miR-335-5p regulates cell cycle and metastasis in lung adenocarcinoma by targeting CCNB2. Onco Targets Ther. 13:6255–6263. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chen L, Heikkinen L, Wang C, Yang Y, Sun H and Wong G: Trends in the development of miRNA bioinformatics tools. Brief Bioinform. 20:1836–1852. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Petkova V, Marinova D, Kyurkchiyan S, Stancheva G, Mekov E, Kachakova-Yordanova D, Slavova Y, Kostadinov D, Mitev V and Kaneva R: MiRNA expression profiling in adenocarcinoma and squamous cell lung carcinoma reveals both common and specific deregulated microRNAs. Medicine (Baltimore). 101:e300272022. View Article : Google Scholar : PubMed/NCBI | |
|
Jin X, Chen Y, Chen H, Fei S, Chen D, Cai X, Liu L, Lin B, Su H, Zhao L, et al: Evaluation of tumor-derived exosomal miRNA as potential diagnostic biomarkers for early-stage non-small cell lung cancer using next-generation sequencing. Clin Cancer Res. 23:5311–5319. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Sun Z, Shi K, Yang S, Liu J, Zhou Q, Wang G, Song J, Li Z, Zhang Z and Yuan W: Effect of exosomal miRNA on cancer biology and clinical applications. Mol Cancer. 17:1472018. View Article : Google Scholar : PubMed/NCBI | |
|
Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Saliminejad K, Khorram Khorshid HR, Soleymani Fard S and Ghaffari SH: An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. J Cell Physiol. 234:5451–5465. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Seijo LM, Peled N, Ajona D, Boeri M, Field JK, Sozzi G, Pio R, Zulueta JJ, Spira A, Massion PP, et al: Biomarkers in lung cancer screening: Achievements, promises, and challenges. J Thorac Oncol. 14:343–357. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kim Y, Sim J, Kim H, Bang SS, Jee S, Park S and Jang K: MicroRNA-374a expression as a prognostic biomarker in lung adenocarcinoma. J Pathol Transl Med. 53:354–360. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tong L, Han WZ, Wang JL, Sun NN and Zhuang M: MicroRNA-365 inhibits the progression of lung adenocarcinoma through targeting ETS1 and inactivating AKT/mTOR pathway. Eur Rev Med Pharmacol Sci. 24:4836–4845. 2020.PubMed/NCBI | |
|
Kim Y, Kim H, Bang S, Jee S and Jang K: MicroRNA-130b functions as an oncogene and is a predictive marker of poor prognosis in lung adenocarcinoma. Lab Invest. 101:155–164. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Sun Y, Mei H, Xu C, Tang H and Wei W: Circulating microRNA-339-5p and −21 in plasma as an early detection predictors of lung adenocarcinoma. Pathol Res Pract. 214:119–125. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Li X and Wu X: MiR-21-5p promotes the progression of non-small-cell lung cancer by regulating the expression of SMAD7. Onco Targets Ther. 11:8445–8454. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chen J, Li X, Yang L and Zhang J: Long non-coding RNA LINC01969 promotes ovarian cancer by regulating the miR-144-5p/LARP1 axis as a competing endogenous RNA. Front Cell Dev Biol. 8:6257302021. View Article : Google Scholar : PubMed/NCBI | |
|
Perlikos F, Harrington KJ and Syrigos KN: Key molecular mechanisms in lung cancer invasion and metastasis: A comprehensive review. Crit Rev Oncol Hematol. 87:1–11. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Verma V and Lautenschlaeger T: MicroRNAs in non-small cell lung cancer invasion and metastasis: From the perspective of the radiation oncologist. Expert Rev Anticancer Ther. 16:767–774. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Pastushenko I and Blanpain C: EMT transition states during tumor progression and metastasis. Trends Cell Biol. 29:212–226. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Bukowski K, Kciuk M and Kontek R: Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 21:32332020. View Article : Google Scholar : PubMed/NCBI | |
|
Baskar R, Lee KA, Yeo R and Yeoh KW: Cancer and radiation therapy: Current advances and future directions. Int J Med Sci. 9:193–199. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Mishra S, Yadav T and Rani V: Exploring miRNA based approaches in cancer diagnostics and therapeutics. Crit Rev Oncol Hematol. 98:12–23. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang N, Zou C, Zhu Y, Luo Y, Chen L, Lei Y, Tang K, Sun Y, Zhang W, Li S, et al: HIF-1α-regulated miR-1275 maintains stem cell-like phenotypes and promotes the progression of LUAD by simultaneously activating Wnt/β-catenin and Notch signaling. Theranostics. 10:2553–2570. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Du X, Wang S, Liu X, He T, Lin X, Wu S, Wang D, Li J, Huang W and Yang H: MiR-1307-5p targeting TRAF3 upregulates the MAPK/NF-κB pathway and promotes lung adenocarcinoma proliferation. Cancer Cell Int. 20:5022020. View Article : Google Scholar : PubMed/NCBI | |
|
He T, Shen H, Wang S, Wang Y, He Z, Zhu L, Du X, Wang D, Li J, Zhong S, et al: MicroRNA-3613-5p promotes lung adenocarcinoma cell proliferation through a RELA and AKT/MAPK positive feedback loop. Mol Ther Nucleic Acids. 22:572–583. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ma DB, Qin MM, Shi L and Ding XM: MicroRNA-6077 enhances the sensitivity of patients-derived lung adenocarcinoma cells to anlotinib by repressing the activation of glucose transporter 1 pathway. Cell Signal. 64:1093912019. View Article : Google Scholar : PubMed/NCBI | |
|
Song M and Xing X: miR-6742-5p regulates the invasion and migration of lung adenocarcinoma cells via mediating FGF8/ERK12/MMP9/MMP2 signaling pathway. Aging (Albany NY). 15:53–69. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Fang H, Wu W and Wu Z: miR-382-3p downregulation contributes to the carcinogenesis of lung adenocarcinoma by promoting AKT SUMOylation and phosphorylation. Exp Ther Med. 24:4402022. View Article : Google Scholar : PubMed/NCBI | |
|
Lin Q: MicroRNA-1-3p affects lung adenocarcinoma progression through E2F8 and regulating NF-кB pathway. Cytokine. 156:1559222022. View Article : Google Scholar : PubMed/NCBI | |
|
Sun Y, Liu W, Zhao Q, Zhang R, Wang J, Pan P, Shang H, Liu C and Wang C: Down-regulating the expression of miRNA-21 inhibits the glucose metabolism of A549/DDP cells and promotes cell death through the PI3K/AKT/mTOR/HIF-1α pathway. Front Oncol. 11:6535962021. View Article : Google Scholar : PubMed/NCBI | |
|
Edmonds MD, Boyd KL, Moyo T, Mitra R, Duszynski R, Arrate MP, Chen X, Zhao Z, Blackwell TS, Andl T and Eischen CM: MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer. J Clin Invest. 126:349–364. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Qu J, Li M, An J, Zhao B, Zhong W, Gu Q, Cao L, Yang H and Hu C: MicroRNA-33b inhibits lung adenocarcinoma cell growth, invasion, and epithelial-mesenchymal transition by suppressing Wnt/β-catenin/ZEB1 signaling. Int J Oncol. 47:2141–2152. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Y, Zhang Y, Li Y, Liu L, Li Z, Liu Y and Xiao Y: MicroRNA-106a-5p promotes the proliferation, autophagy and migration of lung adenocarcinoma cells by targeting LKB1/AMPK. Exp Ther Med. 22:14222021. View Article : Google Scholar : PubMed/NCBI | |
|
Fan X, Liang Y, Liu Y, Bai Y, Yang C and Xu S: The upregulation of TMPRSS4, partly ascribed to the downregulation of miR-125a-5p, promotes the growth of human lung adenocarcinoma via the NF-κB signaling pathway. Int J Oncol. 53:148–158. 2018.PubMed/NCBI | |
|
Ghoshal-Gupta S, Kutiyanawalla A, Lee BR, Ojha J, Nurani A, Mondal AK, Kolhe R, Rojiani AM and Rojiani MV: TIMP-1 downregulation modulates miR-125a-5p expression and triggers the apoptotic pathway. Oncotarget. 9:8941–8956. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Meng H, Li B, Xu W, Ding R, Xu S, Wu Q and Zhang Y: miR-140-3p enhances the sensitivity of LUAD cells to antitumor agents by targeting the ADAM10/Notch pathway. J Cancer. 13:3660–3673. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang WS, Huang CL, Zhang J, Xu F and Dai XH: MicroRNA-149 inhibits the progression of lung adenocarcinoma through targeting RAP1B and inactivating Wnt/β-catenin pathway. Eur Rev Med Pharmacol Sci. 24:4846–4854. 2020.PubMed/NCBI | |
|
Liu J, Xing Y and Rong L: miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway. Oncol Rep. 39:1631–1639. 2018.PubMed/NCBI | |
|
Seidl C, Panzitt K, Bertsch A, Brcic L, Schein S, Mack M, Leithner K, Prinz F, Olschewski H, Kornmueller K and Hrzenjak A: MicroRNA-182-5p regulates hedgehog signaling pathway and chemosensitivity of cisplatin-resistant lung adenocarcinoma cells via targeting GLI2. Cancer Lett. 469:266–276. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Guo L, Wang J, Yang P, Lu Q, Zhang T and Yang Y: MicroRNA-200 promotes lung cancer cell growth through FOG2-independent AKT activation. IUBMB Life. 67:720–725. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X, Gao X, Zhang W, Zhu T, Bi W and Zhang Y: MicroRNA-204 deregulation in lung adenocarcinoma controls the biological behaviors of endothelial cells potentially by modulating Janus kinase 2-signal transducer and activator of transcription 3 pathway. IUBMB Life. 70:81–91. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Watt K, Newsted D, Voorand E, Gooding RJ, Majewski A, Truesdell P, Yao B, Tuschl T, Renwick N and Craig AW: MicroRNA-206 suppresses TGF-β signalling to limit tumor growth and metastasis in lung adenocarcinoma. Cell Signal. 50:25–36. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lv Q, Hu JX, Li YJ, Xie N, Song DD, Zhao W, Yan YF, Li BS, Wang PY and Xie SY: MiR-320a effectively suppresses lung adenocarcinoma cell proliferation and metastasis by regulating STAT3 signals. Cancer Biol Ther. 18:142–151. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou QY, Gui SY, Zhang P and Wang M: Upregulation of miR-345-5p suppresses cell growth of lung adenocarcinoma by regulating ras homolog family member A (RhoA) and Rho/Rho associated protein kinase (Rho/ROCK) pathway. Chin Med J (Engl). 134:2619–2628. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Chen T, Huang H, Jiang Y, Yang L, Lin Z, He H, Liu T, Wu B, Chen J, et al: miR-363-3p inhibits tumor growth by targeting PCNA in lung adenocarcinoma. Oncotarget. 8:20133–20144. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Zhang S, Bao H, Mu S, Zhang B, Ma H and Ma S: MicroRNA-365 promotes lung carcinogenesis by downregulating the USP33/SLIT2/ROBO1 signalling pathway. Cancer Cell Int. 18:642018. View Article : Google Scholar : PubMed/NCBI | |
|
Xuan YW, Liao M, Zhai WL, Peng LJ and Tang Y: MicroRNA-381 inhibits lung adenocarcinoma cell biological progression by directly targeting LMO3 through regulation of the PI3K/Akt signaling pathway and epithelial-to-mesenchymal transition. Eur Rev Med Pharmacol Sci. 23:8411–8421. 2019.PubMed/NCBI | |
|
He B, Wu C, Sun W, Qiu Y, Li J, Liu Z, Jing T, Wang H and Liao Y: miR-383 increases the cisplatin sensitivity of lung adenocarcinoma cells through inhibition of the RBM24-mediated NF-κB signaling pathway. Int J Oncol. 59:872021. View Article : Google Scholar : PubMed/NCBI | |
|
Wan L, Zhu L, Xu J, Lu B, Yang Y, Liu F and Wang Z: MicroRNA-409-3p functions as a tumor suppressor in human lung adenocarcinoma by targeting c-Met. Cell Physiol Biochem. 34:1273–1290. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ma J, Huang W, Zhu C, Sun X, Zhang Q, Zhang L, Qi Q, Bai X, Feng Y and Wang C: miR-423-3p activates FAK signaling pathway to drive EMT process and tumor growth in lung adenocarcinoma through targeting CYBRD1. J Clin Lab Anal. 35:e240442021. View Article : Google Scholar : PubMed/NCBI | |
|
Liu R, Wang F, Guo Y, Yang J, Chen S, Gao X and Wang X: MicroRNA-425 promotes the development of lung adenocarcinoma via targeting A disintegrin and metalloproteinases 9 (ADAM9). Onco Targets Ther. 11:4065–4073. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chen D, Huang J, Zhang K, Pan B, Chen J, De W, Wang R and Chen L: MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc. Eur J Cancer. 50:3050–3067. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Li Z, Jiang D and Yang S: MiR-490-3p inhibits the malignant progression of lung adenocarcinoma. Cancer Manag Res. 12:10975–10984. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Duan J, Wang L, Shang L, Yang S, Wu H, Huang Y and Miao Y: miR-152/TNS1 axis inhibits non-small cell lung cancer progression through Akt/mTOR/RhoA pathway. Biosci Rep. 41:BSR202015392021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhijun Z and Jingkang H: MicroRNA-520e suppresses non-small-cell lung cancer cell growth by targeting Zbtb7a-mediated Wnt signaling pathway. Biochem Biophys Res Commun. 486:49–56. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang Z, Zhang J, Chen F and Sun Y: MiR-148b suppressed non-small cell lung cancer progression via inhibiting ALCAM through the NF-κB signaling pathway. Thorac Cancer. 11:415–425. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang W, Wei K, Pan C, Li H, Cao J, Han X, Tang Y, Zhu S, Yuan W, He Y, et al: MicroRNA-1258 suppresses tumour progression via GRB2/Ras/Erk pathway in non-small-cell lung cancer. Cell Prolif. 51:e125022018. View Article : Google Scholar : PubMed/NCBI | |
|
Wu T, Hu H, Zhang T, Jiang L, Li X, Liu S, Zheng C, Yan G, Chen W, Ning Y, et al: miR-25 promotes cell proliferation, migration, and invasion of non-small-cell lung cancer by targeting the LATS2/YAP signaling pathway. Oxid Med Cell Longev. 2019:97197232019. View Article : Google Scholar : PubMed/NCBI | |
|
Ding X, Zhong T, Jiang L, Huang J, Xia Y and Hu R: miR-25 enhances cell migration and invasion in non-small-cell lung cancer cells via ERK signaling pathway by inhibiting KLF4. Mol Med Rep. 17:7005–7016. 2018.PubMed/NCBI | |
|
Hu Z, Xiao D, Qiu T, Li J and Liu Z: MicroRNA-103a curtails the stemness of non-small cell lung cancer cells by binding OTUB1 via the hippo signaling pathway. Technol Cancer Res Treat. 19:15330338209716432020. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang K, Shen M, Chen Y and Xu W: miR-150 promotes the proliferation and migration of non-small cell lung cancer cells by regulating the SIRT2/JMJD2A signaling pathway. Oncol Rep. 40:943–951. 2018.PubMed/NCBI | |
|
Xu G, Cai J, Wang L, Jiang L, Huang J, Hu R and Ding F: MicroRNA-30e-5p suppresses non-small cell lung cancer tumorigenesis by regulating USP22-mediated Sirt1/JAK/STAT3 signaling. Exp Cell Res. 362:268–278. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang JX, Zhai JF, Yang XT and Wang J: MicroRNA-132 inhibits migration, invasion and epithelial-mesenchymal transition by regulating TGFβ1/Smad2 in human non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 20:3793–3801. 2016.PubMed/NCBI | |
|
Revathidevi S and Munirajan AK: Akt in cancer: Mediator and more. Semin Cancer Biol. 59:80–91. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ward SG, Westwick J and Harris S: Sat-Nav for T cells: Role of PI3K isoforms and lipid phosphatases in migration of T lymphocytes. Immunol Lett. 138:15–18. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Altomare DA and Testa JR: Perturbations of the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Akbarzadeh M, Mihanfar A, Akbarzadeh S, Yousefi B and Majidinia M: Crosstalk between miRNA and PI3K/AKT/mTOR signaling pathway in cancer. Life Sci. 285:1199842021. View Article : Google Scholar : PubMed/NCBI | |
|
Zou S, Tong Q, Liu B, Huang W, Tian Y and Fu X: Targeting STAT3 in Cancer Immunotherapy. Mol Cancer. 19:1452020. View Article : Google Scholar : PubMed/NCBI | |
|
Johnson DE, O'Keefe RA and Grandis JR: Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 15:234–248. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhan T, Rindtorff N and Boutros M: Wnt signaling in cancer. Oncogene. 36:1461–1473. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, Yang SX and Ivy SP: Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: Clinical update. Nat Rev Clin Oncol. 12:445–464. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Huang S: mTOR signaling in metabolism and cancer. Cells. 9:22782020. View Article : Google Scholar : PubMed/NCBI | |
|
Hua H, Kong Q, Zhang H, Wang J, Luo T and Jiang Y: Targeting mTOR for cancer therapy. J Hematol Oncol. 12:712019. View Article : Google Scholar : PubMed/NCBI | |
|
Kryczka J, Kryczka J, Czarnecka-Chrebelska KH and Brzeziańska-Lasota E: Molecular mechanisms of chemoresistance induced by cisplatin in NSCLC cancer therapy. Int J Mol Sci. 22:88852021. View Article : Google Scholar : PubMed/NCBI | |
|
Dolcet X, Llobet D, Pallares J and Matias-Guiu X: NF-kB in development and progression of human cancer. Virchows Arch. 446:475–482. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Bonizzi G and Karin M: The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25:280–288. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Lee S, Rauch J and Kolch W: Targeting MAPK signaling in cancer: Mechanisms of drug resistance and sensitivity. Int J Mol Sci. 21:11022020. View Article : Google Scholar : PubMed/NCBI | |
|
Asl ER, Amini M, Najafi S, Mansoori B, Mokhtarzadeh A, Mohammadi A, Lotfinejad P, Bagheri M, Shirjang S, Lotfi Z, et al: Interplay between MAPK/ERK signaling pathway and MicroRNAs: A crucial mechanism regulating cancer cell metabolism and tumor progression. Life Sci. 278:1194992021. View Article : Google Scholar : PubMed/NCBI | |
|
Qi X, Zhang DH, Wu N, Xiao JH, Wang X and Ma W: ceRNA in cancer: Possible functions and clinical implications. J Med Genet. 52:710–718. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Arancio W, Pizzolanti G, Genovese SI, Baiamonte C and Giordano C: Competing endogenous RNA and interactome bioinformatic analyses on human telomerase. Rejuvenation Res. 17:161–167. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yang S, Liu T, Sun Y and Liang X: The long noncoding RNA LINC00483 promotes lung adenocarcinoma progression by sponging miR-204-3p. Cell Mol Biol Lett. 24:702019. View Article : Google Scholar : PubMed/NCBI | |
|
Qian Y, Zhang Y, Ji H, Shen Y, Zheng L, Cheng S and Lu X: LINC01089 suppresses lung adenocarcinoma cell proliferation and migration via miR-301b-3p/STARD13 axis. BMC Pulm Med. 21:2422021. View Article : Google Scholar : PubMed/NCBI | |
|
Cai Y, Sheng Z, Chen Y and Wang J: LncRNA HMMR-AS1 promotes proliferation and metastasis of lung adenocarcinoma by regulating MiR-138/sirt6 axis. Aging (Albany NY). 11:3041–3054. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chen W, Li X, Du B, Cui Y, Ma Y and Li Y: The long noncoding RNA HOXA11-AS promotes lung adenocarcinoma proliferation and glycolysis via the microRNA-148b-3p/PKM2 axis. Cancer Med. 12:4421–4433. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Chen H, Liu M, Xiong J and Song Z: Long noncoding RNA LINC00520 accelerates lung adenocarcinoma progression via miR-1252-5p/FOXR2 pathway. Hum Cell. 34:478–490. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Li W, Lin Z, Hu J, Wang J, Ren Y, Wei B, Fan Y and Yang Y: The long noncoding RNA Linc01833 enhances lung adenocarcinoma progression via MiR-519e-3p/S100A4 axis. Cancer Manag Res. 12:11157–11167. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Dong HX, Wang R, Jin XY, Zeng J and Pan J: LncRNA DGCR5 promotes lung adenocarcinoma (LUAD) progression via inhibiting hsa-mir-22-3p. J Cell Physiol. 233:4126–4136. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bai J, Li H, Chen X, Chen L, Hu Y, Liu L, Zhao Y, Zuo W, Zhang B and Yin C: LncRNA-AC009948.5 promotes invasion and metastasis of lung adenocarcinoma by binding to miR-186-5p. Front Oncol. 12:9499512022. View Article : Google Scholar : PubMed/NCBI | |
|
Huang J, Yu Q, Zhou Y, Chu Y, Jiang F and Wang Q: FAM201A knockdown inhibits proliferation and invasion of lung adenocarcinoma cells by regulating miR-7515/GLO1 axis. J Cell Physiol. 236:5620–5632. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Ge Z, Liu H, Ji T, Liu Q, Zhang L, Zhu P, Li L and Zhu L: Long non-coding RNA 00960 promoted the aggressiveness of lung adenocarcinoma via the miR-124a/SphK1 axis. Bioengineered. 13:1276–1287. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Tai G, Fu H, Bai H, Liu H, Li L and Song T: Long non-coding RNA GLIDR accelerates the tumorigenesis of lung adenocarcinoma by miR-1270/TCF12 axis. Cell Cycle. 20:1653–1662. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Mu X, Wu H, Liu J, Hu X, Wu H, Chen L, Liu W, Luo S and Zhao Y: Long noncoding RNA TMPO-AS1 promotes lung adenocarcinoma progression and is negatively regulated by miR-383-5p. Biomed Pharmacother. 125:1099892020. View Article : Google Scholar : PubMed/NCBI | |
|
Liu T, Yang C, Wang W and Liu C: LncRNA SGMS1-AS1 regulates lung adenocarcinoma cell proliferation, migration, invasion, and EMT progression via miR-106a-5p/MYLI9 axis. Thorac Cancer. 12:2104–2112. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Q, Xu Z, Zhu K, Lin J and Ye B: LINC00346 sponges miR-30c-2-3p to promote the development of lung adenocarcinoma by targeting MYBL2 and regulating CELL CYCLE signaling pathway. Front Oncol. 11:6872082021. View Article : Google Scholar : PubMed/NCBI | |
|
Yao Y, Hua Q and Zhou Y: CircRNA has_circ_0006427 suppresses the progression of lung adenocarcinoma by regulating miR-6783-3p/DKK1 axis and inactivating Wnt/β-catenin signaling pathway. Biochem Biophys Res Commun. 508:37–45. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Du J, Zhang G, Qiu H, Yu H and Yuan W: The novel circular RNA circ-CAMK2A enhances lung adenocarcinoma metastasis by regulating the miR-615-5p/fibronectin 1 pathway. Cell Mol Biol Lett. 24:722019. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Su S, Ye D, Yu Z, Lu W and Liu L: Hsa_circ_0020850 promotes the malignant behaviors of lung adenocarcinoma by regulating miR-326/BECN1 axis. World J Surg Oncol. 20:132022. View Article : Google Scholar : PubMed/NCBI | |
|
Ma D, Liu H, Qin Y, Li D, Cui Y, Li L, He J, Chen Y and Zhou X: Circ_0007142/miR-186/FOXK1 axis promoted lung adenocarcinoma progression. Am J Transl Res. 12:4728–4738. 2020.PubMed/NCBI | |
|
Huang C, Yue W, Li L, Li S, Gao C, Si L, Qi L, Cheng C, Lu M, Chen G, et al: Circular RNA hsa-circ-000881 suppresses the progression of lung adenocarcinoma in vitro via a miR-665/PRICKLE2 axis. Ann Transl Med. 9:4982021. View Article : Google Scholar : PubMed/NCBI | |
|
Shi Q and Ju JG: Circ_0001998 regulates the proliferation, invasion, and apoptosis of lung adenocarcinoma via sponging miR-145. Evid Based Complement Alternat Med. 2022:64461502022.PubMed/NCBI | |
|
Fan J, Xia X and Fan Z: Hsa_circ_0129047 regulates the miR-375/ACVRL1 axis to attenuate the progression of lung adenocarcinoma. J Clin Lab Anal. 36:e245912022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang B, Chen M, Jiang N, Shi K and Qian R: A regulatory circuit of circ-MTO1/miR-17/QKI-5 inhibits the proliferation of lung adenocarcinoma. Cancer Biol Ther. 20:1127–1135. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wei W, Wang C, Wang L and Zhang J: circ_0020123 promotes cell proliferation and migration in lung adenocarcinoma via PDZD8. Open Med (Wars). 17:536–549. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Sun Z: Circular RNA hsa_circ_0001588 promotes the malignant progression of lung adenocarcinoma by modulating miR-524-3p/NACC1 signaling. Life Sci. 259:1181572020. View Article : Google Scholar : PubMed/NCBI | |
|
Cao F, Liu S, Li Z, Meng L, Sang M and Shan B: Activation of circ_0072088/miR-1261/PIK3CA pathway accelerates lung adenocarcinoma progression. Thorac Cancer. 13:1548–1557. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Panda AC: Circular RNAs Act as miRNA sponges. Adv Exp Med Biol. 1087:67–79. 2018. View Article : Google Scholar : PubMed/NCBI |
